More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 125-131

  Wang, Jiaoli ^a   Wang, Limin ^a   Lin, Zhendong ^b   Tao, Lisha ^b   Chen, Ming ^b  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD40; Dendritic cells; Exosomes; Lung cancers

Indexed keywords

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; EXOSOMES; FEMALE; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 84893873412     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1759     Document Type: Article

References (23)

1. Sugimura H, Nichols FC, Yang P, et al: Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 83: 409-418, 2007
2. Théry C, Zitvogel L and Amigorena S: Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579, 2002
3. Lamparski HG, Metha-Damani A, Yao JY, et al: Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 270: 211-226, 2002
4. Chaput N and Théry C: Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 33: 419-440, 2011
5. Ohshima K, Inoue K, Fujiwara A, et al: Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 5: e13247, 2010
6. Zhang J, Zhang Y, Luo C, Xia Y, Chen H and Wu X: Glycosyl- phosphatidylinositol-anchored interleukin-2 expressed on tumor-derived exosomes induces antitumor immune response in vitro. Tumori 96: 452-459, 2010
7. Zhang Y, Wu XH, Luo CL, Zhang JM, He BC and Chen G: Interleukin-12- anchored exosomes increase cytotoxicity of T lymphocytes by reversing the JAK/STAT pathway impaired by tumor-derived exosomes. Int J Mol Med 25: 695-700, 2010
8. Dai S, Wan T, Wang B, et al: More efficient induction of HLA-A.0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 11: 7554-7563, 2005
9. Xiu F, Cai Z, Yang Y, Wang X, Wang J and Cao X: Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J Mol Med (Berl) 85: 511-521, 2007.
10. Armitage RJ, Fanslow WC, Strockbine L, et al: Molecular and biological characterization of a murine ligand for CD40. Nature 357: 80-82, 1992.
11. Melief CJ: Cancer immunotherapy by dendritic cells. Immunity 29: 372-383, 2008.
12. Dohnal AM, Luger R, Paul P, Fuchs D and Felzmann T: CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression. J Cell Mol Med 13: 1741-1750, 2009.
13. Elmetwali T, Searle PF, McNeish I, Young LS and Palmer DH: CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Mol Cancer 9: 52, 2010.
14. van Kooten C and Banchereau J: CD40-CD40 ligand. J Leukoc Biol 67: 2-17, 2000.
15. Van Nuffel AM, Corthals J, Neyns B, Heirman C, Thielemans K and Bonehill A: Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Methods Mol Biol 629: 405-452, 2010.
16. Dai S, Zhou X, Wang B, et al: Enhanced induction of dendritic cell maturation and HLA-A.0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med (Berl) 84: 1067-1076, 2006.
17. Chen W, Wang J, Shao C, et al: Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 36: 1598-1607, 2006.
18. Miller MJ, Foy KC and Kaumaya PT: Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 15: 166-176, 2013.
19. Escudier B, Dorval T, Chaput N, et al: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 3: 10, 2005.
20. Morse MA, Garst J, Osada T, et al: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3: 9, 2005.
21. Wei H, Wang H, Lu B, et al: Cancer immunotherapy using in vitro genetically modified targeted dendritic cells. Cancer Res 68: 3854-3862, 2008.
22. Perrot I, Blanchard D, Freymond N, et al: Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178: 2763-2769, 2007.
23. Chen T, Guo J, Yang M, Zhu X and Cao X: Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine, J Immunol 186: 2219-2228, 2011.